Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0458 • ACR Convergence 2024
Long-Term Outcomes in Seronegative Rheumatoid Arthritis
Bradly Kimbrough¹, Cynthia Crowson², Sara Achenbach³ and Elena Myasoedova², ¹Mayo Clinic Rochester, Rochester, MN, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Rochester, Rochester, MN
Background/Purpose: Seronegative rheumatoid arthritis (RA) is a heterogenous disease distinct from seropositive RA regarding genetic risk factors, pathobiology, and prognosis. Notably, recent studies have shown…
Abstract Number: 0474 • ACR Convergence 2024
Association Between Rheumatoid Arthritis and Survival After Cancer: A Systematic Literature Review and Meta-analysis
Joshua Hsieh¹, Avneet Kaur², Hemant Khandelia³, Teresa Jewell⁴, Aman Singh⁵, Lauren Barkley⁶, Ishan Bansal⁷, Simmi Oberoi⁸ and Namrata Singh⁹, ¹Lakeside High School, Seattle, WA, ²SUNY Upstate, Buffalo, NY, ³AIIMS, New Delhi, Delhi, India, ⁴University of Washington, Seattle, WA, ⁵Rajindra Hospital, Patiala, Punjab, India, ⁶Brandeis University, Boston, MA, ⁷Yale University, New Haven, CT, ⁸Rajindra Hospital, New Delhi, India, ⁹University of Washington, Bellevue, WA
Background/Purpose: Increasing evidence suggests that inflammation, a hallmark of rheumatoid arthritis (RA), is associated with an elevated risk of cancer and can influence cancer outcomes.…
Abstract Number: 0492 • ACR Convergence 2024
A Machine Learning Model for the Early Identification of Rheumatoid Arthritis: Development and Validation
Michael Dreyfuss¹, Yonatan Jenudi², Dan Riesel³, Or Ramni³, Daniel Underberger⁴, Benjamin Getz⁵, Shlomit Steinberg-Koch³, Douglas White⁶ and Elena Myasoedova⁷, ¹Predicta Med, Ramat Gan, Israel, ²[email protected], Ramat Gan, Israel, ³Predicta Med Analytics Ltd., Ramat Gan, Israel, ⁴Predicta Med Analytics Ltd., Bridgeport, CT, ⁵CTO, Ramat Gan, Israel, ⁶Gundersen Health System, Onalaska, WI, ⁷Mayo Clinic, Rochester, MN
Background/Purpose: Patients with rheumatoid arthritis often experience clinically significant delays in diagnosis (Sørensen et al., 2015; Raza et al., 2011). RA can present similarly to…
Abstract Number: 0508 • ACR Convergence 2024
Real-World Evidence for GP2015 in Patients with Rheumatoid Arthritis: Safety Outcomes from German Observational Data
Xenofon Baraliakos¹, Cristofer Salvati², Elena Bachinskaya², Samriddhi Sinha² and Klaus Krüger³, ¹Rheumazentrum Ruhrgebiet Herne, and Ruhr-University Bochum, Bochum, Germany, ²Medical Affairs, Sandoz Hexal AG, Holzkirchen, Germany, Holzkirchen, Germany, ³Rheumatologisches Praxiszentrum, Munich, Germany, München, Germany
Background/Purpose: GP2015 is an etanercept biosimilar indicated for the treatment of rheumatoid arthritis (RA).1 The objective of this abstract is to describe the baseline characteristics…
Abstract Number: 0525 • ACR Convergence 2024
Assess the Effect of Increasing the Dose of Folic Acid Supplementation in Patients of Rheumatoid Arthritis with Methotrexate Intolerance – A Randomised Controlled Trial
Varun Dhir¹, Harshith Sai Koneti², Aman Sharma³, sanjay jain⁴ and shankar naidu⁵, ¹PGIMER, CHD, INDIA, CHANDIGARH, India, ²PGIMER, Chandigarh, Sangareddy, Telangana, India, ³PGIMER, Chandigarh, India, Chandigarh, Chandigarh, India, ⁴PGIMER, Chandigarh, Chandigarh, India, ⁵PGIMER, Chandigarh, India, Chandigarh, India
Background/Purpose: : Methotrexate (MTX) Intolerance continues to occur in 20-40% patients despite low-dose folic acid (5-10mg per week) supplementation. Would a higher dose of folic…
Abstract Number: 0796 • ACR Convergence 2024
Development and Evaluation of Machine Learning Prediction Models for Hospitalizations Due to Opioid-Related Harms Among New Users with Rheumatic and Musculoskeletal Diseases
Carlos Raul Ramirez Medina¹, Mark Lunt², David Jenkins², William Dixon², Niels Peek³ and Meghna Jani², ¹The University of Manchester, Warrington, United Kingdom, ²University of Manchester, Manchester, United Kingdom, ³THIS Institute , University of Cambridge, Cambridge, United Kingdom
Background/Purpose: England has seen a notable rise in prescription opioid use over the past two decades, leading to some of Europe's highest opioid-related hospital admissions.…
Abstract Number: 0883 • ACR Convergence 2024
The Study of 62 Circulating Soluble Factors Is Able to Predict the Lack of Response to MTX Treatment in Recently Diagnosed DMARD Naïve Rheumatoid Arthritis Smoker and Non-Smoker Patients
Jorge Monserrat¹, Cristina Bohorquez², Ana Maria Gómez³, Elena Rabadán Rubio⁴, Raquel Sánchez³, Atusa Movasat⁵, Lucia Ruiz⁴, Fernando Albarran Hernandez⁶, Miguel Ángel Ortega¹, Ana Perez⁶ and Melchor Alvarez-Mon⁷, ¹Universidad de Alcalá. IRYCIS, Alcalá de Henares, Madrid, Spain, ²Hospital Universitario Príncipe de Asturias, Alcalá De Henares, Madrid, Spain, ³Universidad de Alcalá, Alcalá de Henares, Madrid, Spain, ⁴Hospital Universitario Principe de Asturias, Alcalá de Henares, Madrid, Spain, ⁵Hospital Universitario Príncipe de Asturias, Madrid, Spain, ⁶Hospital Universitario Principe de Asturias, Alcala de Henares, Madrid, Spain, ⁷Universidad de Alcalá. HUPA. IRYCIS, Madrid, Spain

Background/Purpose: Rheumatoid arthritis (RA) is a highly inflammatory severe chronic autoimmune disorder with an inadequate activation of the immune cells. These cells are responsible for…
Abstract Number: 0940 • ACR Convergence 2024
Trans-endothelial Migration of Synovial Fibroblasts Promotes Arthritis Severity Through a PKD1-mediated Feedback Loop
Jaeyeon Kim, Richard Ainsworth and Nunzio Bottini, Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: The application of single cell genomic approaches to the study of rheumatoid synovium has recently enabled scientists to study the complex relationship between different…
Abstract Number: 1004 • ACR Convergence 2024
Predictors of Post-acute Sequelae of COVID-19 in Patients with Rheumatoid Arthritis: A Retrospective Analysis of a Large Health System in the Midwestern United States
Ernesto Lopez Castillo¹ and Jeffrey Ording², ¹University of Colorado, Denver, CO, ²Advocate Illinois Masonic Medical Center, Chicago, IL
Background/Purpose: Evidence suggests that patients with autoimmune diseases or immunosuppressive conditions have a higher risk of poor outcomes related to Coronavirus disease 2019 (COVID-19) infection.…
Abstract Number: 1047 • ACR Convergence 2024
Impact of Treatment Switching on Adherence in Members with Rheumatoid Arthritis, Psoriatic Arthritis, or Systemic Lupus Erythematosus
Jean Park¹, Cliff Rutter², Elisea Avalos-Reyes³, Mary Anderson⁴, Will Cavers⁵, Dorothea Verbrugge⁶ and Kjel Johnson⁷, ¹CVS Health, Hartford, CT, ²CVS Health, Fair Oaks Ranch, TX, ³CVS Health, Highland Village, TX, ⁴CVS Health, Irving, TX, ⁵CVS Health, Palm Beach Gardens, ⁶CVS Health, Salt Lake City, ⁷CVS Health, Tampa
Background/Purpose: Switching treatment from conventional to biologic disease-modifying antirheumatic drugs (DMARDs) is a common practice for managing autoimmune diseases such as rheumatoid arthritis (RA), psoriatic…
Abstract Number: 1316 • ACR Convergence 2024
Dual Therapy with a JAKi and bDMARD in Patients with Standard Treatment Resistant Rheumatic Disease: A Case Series
Bella Garg¹, John Antowan² and daniel Furst³, ¹Centinela Hospital Medical Center, Inglewood, CA, ²UCLA, Los Angeles, ³Pacific Arthritis Center, Inglewood
Background/Purpose: Due to concerns about side effects, combined JAK inhibitors (JAKi) and biologic DMARDs (bDMARDs) have not been recommended for rheumatologic conditions. However, combining them…
Abstract Number: 1340 • ACR Convergence 2024
Characteristics and Long-term Outcomes of Patients with Rheumatoid Arthritis and Concurrent Calcium Pyrophosphate Deposition Disease
Natalie Schanzer¹, Ted Mikuls², Bryant England², Katherine Wysham³, Jorge Rojas⁴, Sauer brian⁵, Beth Wallace⁶, Rachel Elam⁷, Andreas Reimold⁸, Gail Kerr⁹, John Richards¹⁰, Gary Kunkel¹¹, Iris Lee¹², Isaac Smith¹³, Paul Monach¹⁴, grant Cannon¹⁵ and Joshua Baker¹⁶, ¹Perelman School of Medicine at University of Pennsylvania, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴Seattle VA, Mexico, Mexico, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁷Augusta University, Evans, GA, ⁸Dallas VA Medical Center, Dallas, TX, ⁹Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹⁰Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ¹¹University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ¹²Washington University in St Louis, Saint Louis, MO, ¹³Duke University Hospital, Durham, NC, ¹⁴VA Boston Healthcare System, Boston, MA, ¹⁵University of Utah and Salt Lake City VA, Salt Lake City, UT, ¹⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: Calcium pyrophosphate deposition disease (CPPD) is a common crystalline arthritis that can both present alongside rheumatoid arthritis (RA) and, given its similar pattern of…
Abstract Number: 1356 • ACR Convergence 2024
Association Between Vascular Inflammation and Kidney Function in Patients with Rheumatoid Arthritis: Secondary Analysis of TARGET Trial
Sho Fukui¹, Ahmed Tawakol², Wolfgang Winkelmayer³, Leah Santacroce⁴, Jon Giles⁵, Katherine Liao⁴, Joan Bathon⁶ and Daniel Solomon⁷, ¹Brigham and Women's Hospital, Brookline, MA, ²Massachusetts General Hospital/Harvard Medical School, Boston, MA, ³Baylor College of Medicine, Houston, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Cedars Sinai Medical Center, Los Angeles, CA, ⁶Columbia University, NEW YORK, NY, ⁷Brigham and Women's Hospital, Newton, MA
Background/Purpose: Kidney dysfunction is a common complication in patients with rheumatoid arthritis (RA). More severe disease activity is associated with a larger decline in the…
Abstract Number: 1372 • ACR Convergence 2024
Upadacitinib and Other JAK Inhibitors in the Treatment of Rheumatoid Arthritis – Interstitial Lung Disease. National Multicenter Study Clinical Practice.
Ana Serrano-Combarro¹, Belén Atienza-Mateo², Jesús Loarce³, Leticia del Olmo Perez⁴, Sara García-Pérez⁵, Guillermo Gonzalez Mozo de Rosales⁶, José Rosas-Gómez de Salazar⁷, Ana Urruticoechea-Arana⁸, Andrea García-Valle⁹, Juan Moreno Morales¹⁰, María Martín López¹¹, Patricia Lopez Viejo¹², Virginia Ruiz-Esquide¹³, Julia Fernandez Melon¹⁴, David Castro-Corredor¹⁵, Ana Fernández-Ortiz¹⁶, Rafael Benito Melero-Gonzalez¹⁷, Carolina Díez Morrondo¹⁸, Desiree Palma¹⁹, Natividad del Val del Amo²⁰, Natalia Mena Vázquez²¹, Alicia García Dorta²², MARÍA JOSÉ PÉREZ GALÁN²³, MARINA SOLEDAD MORENO GARCIA²⁴ and Ricardo Blanco-Alonso²⁵, and on behalf of JAKi in Interstitial Lung Disease Associated with Rheumatoid Arthritis, ¹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, ³Ramón y Cajal University Hospital, Madrid, Madrid, Spain, ⁴HOSPITAL NUESTRA SEÑORA DEL PRADO, TALAVERA DE LA REINA, Spain, ⁵Complejo Hospitalario de Vigo, Vigo, Galicia, Spain, ⁶Basurto University Hospital, Bilbao, Spain, ⁷Hospital Marina Baixa, PALMA DE MALLORCA, Comunidad Valenciana, Spain, ⁸Hospital Son Espases, Palma de Mallorca, Islas Baleares, Spain, ⁹Hospital General Río Carrión, Palencia, Spain, ¹⁰Hospital Universitario Santa Lucia Cartagena, Murcia, Murcia, Spain, ¹¹General University Hospital of Ciudad Real, Ciudad de México, Spain, ¹²Hospital Severo Ochoa, Madrid, Madrid, Spain, ¹³Hospital Clinic de Barcelona, Barcelona, Spain, ¹⁴Hospital Son Espases, Palma, Spain, ¹⁵General University Hospital of Ciudad Real, Santa Cruz de Mudela (Ciudad Real), Spain, ¹⁶Hospital Universitario de Badajoz, Badajoz, Spain, ¹⁷CHU Ourense, O Carballino, Spain, ¹⁸Complejo Asistencial Universitario de Leon, Leon, ¹⁹Hospital Rafael Méndez, Lorca, Murcia, Spain, ²⁰Complejo Hospitalario de Navarra, Pamplona, Spain, ²¹IBIMA, Málaga, Andalucia, Spain, ²²Rheumatologist, La Laguna, Spain, ²³SERVICIO ANDALUZ DE SALUD, GRANADA, Andalucia, Spain, ²⁴Hospital Universitario Miguel Servet, GIJON, Asturias, Spain, ²⁵Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Abatacept and rituximab are the recommended drugs. JAK inhibitors (JAKi) have…
Abstract Number: 1389 • ACR Convergence 2024
Cohort Study on Drug Survival and Tolerability of Adalimumab Biosimilar Transitioning: Pharmaceutical Properties Do Matter
Amy Peeters¹, Maike Wientjes², Wieland Müskens¹, David Ten Cate³, Bart van den Bemt⁴, Noortje van Herwaarden¹ and Alfons den Broeder², ¹Sint maartenskliniek, Nijmegen, Netherlands, ²Sint Maartenskliniek, Ubbergen, Netherlands, ³Sint Maartenskliniek, Rotterdam, Netherlands, ⁴Sint Maartenskliniek / Radboudumc, Ubbergen, Netherlands
Background/Purpose: Since the compound patent on the bio-originator of adalimumab expired, several adalimumab biosimilars (BS) have been introduced. Extensive research shows equivalence in effectiveness and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].